David Warshal

Head, Division of Gynecologic Oncology

Cooper University Health Care
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Warshal is the Head of the Division of Gynecologic Oncology at Cooper University Health Care, USA. His research areas include cervical cancer, endometrial carcinoma, and ovarian cancer, focusing on surgical therapies, quality of life evaluations, and innovative treatments such as gene therapy. He has contributed to various studies assessing patient outcomes and molecular classifications in relation to cancer treatments.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

High mortality rates in ovarian cancer have been linked to recurrence, metastasis, and chemoresistant disease, which are known to involve not only genetic changes but also epigenetic aberrations. In ovarian cancer, adipose-derived stem cells from the omentum (O-ASCs) play a crucial role in supporting the tumor and its tumorigenic microenvironment, further propagating epigenetic abnormalities and dissemination of the disease. Epigallocatechin gallate (EGCG), a DNA methyltransferase inhibitor derived from green tea, and Indole-3-carbinol (I3C), a histone deacetylase inhibitor from cruciferous vegetables, carry promising effects in reprograming aberrant epigenetic modifications in cancer. Therefore, we demonstrate the action of these diet-derived compounds in suppressing the growth of 3D ovarian cancer spheroids or organoids as well as post-treatment cancer recovery through proliferation, migration, invasion, and colony formation assays when compared to the synthetic epigenetic compound Panobinostat with or without standard chemotherapy. Finally, given the regulatory role of the secretome in growth, metastasis, chemoresistance, and relapse of disease, we demonstrate that natural epigenetic compounds can regulate the secretion of protumorigenic growth factors, cytokines, extracellular matrix components, and immunoregulatory markers in human ovarian cancer specimens. While further studies are needed, our results suggest that these treatments could be considered in the future as adjuncts to standard chemotherapy, improving efficiency and patient outcomes.

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Collaborators (3)

Debra Richardson

Professor and Section Chief

University of Kansas Cancer Center

UNITED STATES
View details

Shuyue Ren

-

UNITED STATES
View details

Olga Ostrovsky

Cooper Medical School of Rowan University

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.